Review Article

Why Neurologists Should Remember About Antidepressants

Maxym Konyushok
Therapeutic and preventive center of mental health “Stozhar”, Ukraine
* Corresponding author
DOI icon 10.24018/ejmed.2020.2.4.448

Read Counter
4943

Downloads
431

Citations

Share

Article Sidebar

Submitted 2020-08-17
Published 2020-08-24

Read counter = 4943 times

Table of Contents

Article Main Content

The importance of neurological diseases and mood disorders for human health and life, as well as for health care and society as a whole, cannot be overestimated. Nervous system pathologies such as stroke, neurodegenerative and demyelinating diseases, are one of the leading causes of death and disability in the world, and up to 60% of suicides are associated with depression. Antidepressants are used not only in psychiatric practice, but also in the practice of neurologists. Neurologists prescribe antidepressants to treat depression in neurological patients, chronic pain syndromes and neuropathic pain, panic attacks, eating disorders, premenstrual syndrome and for migraine prevention. The most difficult task for neurologists is to identify depressive disorders that often comorbid neurological diseases. The main property of antidepressants is the ability to increase depressed mood without increasing normal mood and without showing a stimulating effect. Antidepressants also have anti-anxiety, sedative, anti-phobic, anti-panic and somatic effects. When depression is detected in patients with neurological pathology, the prescription of antidepressants is justified not only from the psychiatric (relieving depression and reducing the risk of suicide), but also from the neurological point of view (reducing the risk of complications of neurological pathology and premature mortality from it).

Keywords: depression, antidepressant, neurodegenerative disease, acute cerebrovascular disease, neuropathic pain, Parkinson’s disease, bipolar depression, neurology, stoke, pain, attention deficit hyperactivity disorder, ADHD, disability

References

  1. Baert, I., Feys, H., Daly, D., Troosters, T., & Vanlandewijck, Y. (2012). Are patients 1 year post-stroke active enough to improve their physical health?. Disability and rehabilitation, 34(7), 574-580.
    DOI  |   Google Scholar
  2. Tsarkov, A., & Petlovanyi, P. (2019). Neuropsychiatric Aspects of a Common Problem: Stroke. European Journal of Medical and Health Sciences, 1(3).
    DOI  |   Google Scholar
  3. Tsarkov, A., & Petlovanyi, P. The Role of Lamotrigine in the Treatment of Bipolar Depression.
     Google Scholar
  4. Shibata, M., & Suzuki, N. (2017). Exploring the role of microglia in cortical spreading depression in neurological disease. Journal of Cerebral Blood Flow & Metabolism, 37(4), 1182-1191.
    DOI  |   Google Scholar
  5. Anatolii, T., & Petro, P. (2020). Use of pramipexole in neuropsychiatry. World Journal of Advanced Research and Reviews, 7(2), 82-88.
     Google Scholar
  6. Tsarkov, A., & Petlovanyi, P. (2020). Use of pramipexole in neuropsychiatry. World Journal of Advanced Research and Reviews, 7(2), 82-88.
    DOI  |   Google Scholar
  7. Lebedyn, Z. (2019). The Use of Antidepressants by General Practitioners and Psychiatrists (Personal Experience).
     Google Scholar
  8. Lebedyn, Z. (2020). Antidepressants In General Practice And Psychiatry. European Journal of Medical and Health Sciences, 2(3). https://doi.org/10.24018/ejmed.2020.2.3.318.
    DOI  |   Google Scholar
  9. Lebedyn, Z. (2020). Recommendations For The Management Of Patients With Depression In General Clinical Practice. European Journal of Medical and Health Sciences, 2(4). https://doi.org/10.24018/ejmed.2020.2.4.416.
    DOI  |   Google Scholar
  10. Aström, M., Adolfsson, R., & Asplund, K. (1993). Major depression in stroke patients. A 3-year longitudinal study. Stroke, 24(7), 976-982.
    DOI  |   Google Scholar
  11. Korczyn, A. D., & Halperin, I. (2009). Depression and dementia. Journal of the neurological sciences, 283(1-2), 139-142.
    DOI  |   Google Scholar
  12. Siegert, R. J., & Abernethy, D. A. (2005). Depression in multiple sclerosis: a review. Journal of Neurology, Neurosurgery & Psychiatry, 76(4), 469-475.
    DOI  |   Google Scholar
  13. Thomas, A. J., Kalaria, R. N., & T O’Brien, J. (2004). Depression and vascular disease: what is the relationship?. Journal of affective disorders, 79(1-3), 81-95.
    DOI  |   Google Scholar
  14. Petlovanyi, P., & Tsarkov, A. (2017). Depressive Disorder in Child Psychiatric Practice: A Case Report. Health Press Zambia Bull, 1(5), 9.
     Google Scholar
  15. Tsarkov, A., & Petlovanyi, P. Depressive Disorder in Child Psychiatric Practice: A. The Health Press, 9.
     Google Scholar
  16. Petlovanyi, P., & Tsarkov, A. Child Schizophrenia: Theory and Practice.
     Google Scholar
  17. Rincon, H. G., Granados, M., Unutzer, J., Gomez, M., Duran, R., Badiel, M., ... & Florez, N. (2001). Prevalence, detection and treatment of anxiety, depression, and delirium in the adult critical care unit. Psychosomatics, 42(5), 391-396.
    DOI  |   Google Scholar
  18. Anatolii, T., Patrick, M., & Petro, P. (2020). Uncommon presentation: Folie à deux (Case study). World Journal of Advanced Research and Reviews, 6(3), 043-049.
     Google Scholar
  19. Tsarkov, A., Msoni, P., & Petlovanyi, P. (2020). Uncommon presentation: Folie à deux (Case study). World Journal of Advanced Research and Reviews, 6(3), 043-049.
    DOI  |   Google Scholar
  20. Schneck, C. D. (2002). Bipolar disorder in neurologic illness. Current Treatment Options in Neurology, 4(6), 477-486.
    DOI  |   Google Scholar
  21. Tsarkov, A., & Petlovanyi, P. (2016). Bipolar disorder in child psychiatric practice.
     Google Scholar
  22. Tsarkov, A., & Petlovanyi, P. (2016). Bipolar Disorder in Child Psychiatric Practice: A Case Report. Medical Journal of Zambia, 43(1), 41-46.
     Google Scholar
  23. Sonuga-Barke, E. J., Brandeis, D., Cortese, S., Daley, D., Ferrin, M., Holtmann, M., ... & Dittmann, R. W. (2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry, 170(3), 275-289.
    DOI  |   Google Scholar
  24. Petro, P., & Anatolii, T. (2020). Practical guide and some recommendations for the diagnosis and management of Attention deficit hyperactivity disorder (ADHD). World Journal of Advanced Research and Reviews, 6(3), 257-261.
     Google Scholar
  25. Tsarkov, A., & Petlovanyi, P. (2017). Omega-3 Fatty Acids as an Alternative Treatment for Children with Attention Deficit Hyperactivity Disorder. Imperial Journal of Interdisciplinary Research (IJIR), 3, 1378-1380.
     Google Scholar
  26. Petlovanyi, P., & Tsarkov, A. (2020). Practical guide and some recommendations for the diagnosis and management of Attention deficit hyperactivity disorder (ADHD). World Journal of Advanced Research and Reviews, 6(3), 257-261.
    DOI  |   Google Scholar
  27. Batstra, L., & Frances, A. (2012). DSM-5 further inflates attention deficit hyperactivity disorder. The Journal of nervous and mental disease, 200(6), 486-488.
    DOI  |   Google Scholar
  28. Groenman, A. P., Schweren, L. J., Dietrich, A., & Hoekstra, P. J. (2017). An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Drug Safety, 16(4), 455-464.
    DOI  |   Google Scholar
  29. Bange, F., Le Heuzey, M. F., Acquaviva, E., Delorme, R., & Mouren, M. C. (2013). Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate. Archives de pediatrie: organe officiel de la Societe francaise de pediatrie, 21(1), 108-112.
    DOI  |   Google Scholar
  30. Ladwig, K. H., Roll, G., Breithard, G., Budde, T., & Borggrefe, M. (1994). Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. The Lancet, 343(8888), 20-23.
    DOI  |   Google Scholar
  31. Phiri, C., Tsarkov, A., Petlovanyi, P., & Lingenda, G. Factors Contributing To Oral Diseases and Treatment Needs amongst Mental Patients at Chainama Hills College Hospital, Lusaka, Zambia.
     Google Scholar
  32. Wedding, U., Koch, A., Röhrig, B., Pientka, L., Sauer, H., Höffken, K., & Maurer, I. (2007). Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck's Depression Inventory. Annals of Oncology, 18(11), 1875-1881.
    DOI  |   Google Scholar
  33. Thanacoody, H. R., & Thomas, S. H. (2005). Tricyclic antidepressant poisoning. Toxicological reviews, 24(3), 205-214.
    DOI  |   Google Scholar
  34. Raffaele, R., Rampello, L., Vecchio, I., Tornali, C., & Malaguarnera, M. (1996). Trazodone therapy of the post-stroke depression. Archives of gerontology and geriatrics, 22, 217-220.
    DOI  |   Google Scholar
  35. Paolucci, S. (2017). Advances in antidepressants for treating post-stroke depression. Expert opinion on pharmacotherapy, 18(10), 1011-1017.
    DOI  |   Google Scholar
  36. Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N., & Rochon, P. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, (2).
    DOI  |   Google Scholar
  37. Magai, C., Kennedy, G., Cohen, C. I., & Gomberg, D. (2000). A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. The American Journal of Geriatric Psychiatry, 8(1), 66-74.
    DOI  |   Google Scholar
  38. Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013). Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. The British Journal of Psychiatry, 202(5), 329-335.
    DOI  |   Google Scholar
  39. Schrag, A., Hovris, A., Morley, D., Quinn, N., & Jahanshahi, M. (2006). Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism & related disorders, 12(1), 35-41.
    DOI  |   Google Scholar
  40. Tsarkov, A., & Petlovanyi, P. (2017). Pathological Gambling: The Old Problem of the Modern World. Imperial Journal of Interdisciplinary Research, 3(8), 216-221.
     Google Scholar
  41. Lanteri, P. F., Leguia, A., Doladé, N. G., García, G. C., & Figueras, A. (2018). Drug-induced gambling disorder: A not so rare but underreported condition. Psychiatry research, 269, 593–595.
    DOI  |   Google Scholar
  42. Cetin, K., Johnson, K. L., Ehde, D. M., Kuehn, C. M., Amtmann, D., & Kraft, G. H. (2007). Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Multiple Sclerosis Journal, 13(8), 1046-1053.
    DOI  |   Google Scholar
  43. Lebedyn, Z. (2020). Diagnostic Procedure and Therapeutic Approaches in Nonconvulsive Status Epilepticus (NCSE). European Journal of Medical and Health Sciences, 2(4). https://doi.org/10.24018/ejmed.2020.2.4.426
    DOI  |   Google Scholar
  44. Maguire, M. J., Weston, J., Singh, J., & Marson, A. G. (2014). Antidepressants for people with epilepsy and depression. Cochrane Database of Systematic Reviews, (12).
    DOI  |   Google Scholar
  45. Konyushok, M. (2020). Autism Spectrum Disorder in Adult Patients: Clinical Presentation And Management. European Journal of Medical and Health Sciences, 2(4). https://doi.org/10.24018/ejmed.2020.2.4.428
    DOI  |   Google Scholar
  46. Stewart, M. E., Barnard, L., Pearson, J., Hasan, R., & O’Brien, G. (2006). Presentation of depression in autism and Asperger syndrome: A review. Autism, 10(1), 103-116.
    DOI  |   Google Scholar